Dmitry Arbuck, MD
Psychiatry · Indianapolis, INNPI 1700872033
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.0% of it on its own, with 55 other manufacturers making up the rest. Reporting peaked in 2021 at $15,589 and has fallen 81.0% since, to $2,969 in 2025. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,030 payments — averaging $39.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Teva Pharmaceuticals USA, Inc.$3K
- Biodelivery Sciences International, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Lundbeck LLC$896
- plus $8K from 50 others
What the payments were for
- Speaking & faculty fees$21,38053%
- Travel & lodging$8242%
- Food & beverage$17,65344%
- Education$5251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$20,677
- BELBUCA$1,500
- INGREZZA$244
- VRAYLAR$221
- LATUDA$122
- SPECTRA WAVEWRITER$122
- CAPLYTA$122
- Austedo XR$120
- QULIPTA$114
- Fanapt$114
- PURIFIED CORTROPHIN GEL$113
- ABILIFY ASIMTUFII$101
- ABILIFY MAINTENA$101
How this compares
$40,382 in reported general payments places this provider in the 95th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $237,382 |
| Austedo XrDeutetrabenazine | 14 | $133,365 |
| IngrezzaValbenazine Tosylate | 15 | $121,560 |
| Emgality PenGalcanezumab-Gnlm | 31 | $28,772 |
| Nurtec OdtRimegepant Sulfate | 21 | $27,515 |
| UbrelvyUbrogepant | 12 | $24,234 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $18,544 |
| BelbucaBuprenorphine Hcl | 21 | $12,528 |
| Buprenorphine | 51 | $10,550 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 113 | $9,854 |
| Armodafinil | 29 | $3,976 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,517 |
| Aripiprazole | 25 | $2,999 |
| Lacosamide | 13 | $2,015 |
| Gabapentin | 94 | $1,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,698 | $133,36514 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,210 | $121,56015 claims |
| PfizerNurtec Odt | $483 | $27,51521 claims |
| AbbVieUbrelvy | $24,630 | $24,23412 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $267 | $12,52821 claims |
| Almatica Pharma LLCSertraline Hcl | $57 | $49253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Indianapolis
- Charles BeasleyIndianapolis$129K
- Albert AllenIndianapolis$24K
- Jerad DaltonIndianapolis$20K
- Alan BreierIndianapolis$19K
- Kristen DaussIndianapolis$16K
- Anantha ShekharIndianapolis$13K
- Maria ValenaIndianapolis$11K
- Robert BakerIndianapolis$11K
- Areef KassamIndianapolis$10K
- Judi KnowlesIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.